Janssen Pharmaceutica Nv

Amicus Therapeutics, Inc.

Ortho-mcneil Pharmaceutical Corp.

Philip J Rybczynski

Maud J Urbanski

Mona Patel

Xiaoyan Zhang

Robert E Boyd

Kamlesh A Sheth

Gary Lee

Mary Pat Beavers

Joseph Dudash

Keith T Demarest

Donald W Combs

Min Amy Xiang

Thomas P Burris

Yongzheng Zhang

Bruce E Maryanoff

Michael J Costanzo

David Palling

Benjamin Mugrage

Joseph Gunnet

Stephen C Yabut

Hiayan Bian

Jay M Matthews

Jung S Lee

Kamlesh Sheth

Roxanne Zeck

Richard Look

Xiaoxiang Zhu

Xiaoli Chen

Amy Xiang

Judith Hope Cohen

Min (Amy) Xiang

Dan Fuerst

Alexander Tretyakov

Benjamin Mugrace

Min A Xiang

The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease.

Compositions for preventing and/or treating degenerative disorders of the central nervous system

Described are novel salts of the compound (3R,4R,5S)-5-(difluoromethyl) piperidine-3,4-diol, as well as methods of using the same for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease and/or Parkinson's disease.

Compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system

The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease.

Compositions for preventing and/or treating lysosomal storage disorders

A method for preparing isofagomine, its derivatives, intermediates and salts thereof using novel processes to make isofagomine from D-(&#x2212;)-arabinose and L-(&#x2212;)-xylose.

Method for preparing isofagomine and its derivatives

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating glucokinase mediated disorders. More particularly, the compounds of the present invention are glucokinase modulators useful for treating disorders including, but not limited to, type II diabetes.

Substituted dihydroisoindolones as allosteric modulators of glucokinase

Dihydroisoindolones as allosteric modulators of glucokinase

A novel tartaric acid salt of Isofagomine (Isofagomine tartrate) that can be used for the treatment of Gaucher disease is provided. The invention also provides a crystalline form of isofagomine tartrate, method for preparing the salt, a pharmaceutical composition containing the salt, and a method of treating Gaucher disease.

Tartrate salt of isofagomine and methods of use

The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal insufficiency, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

Substituted spiroheterocycles

The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

Growing community of inventors

Branchburg, NJ, United States of America

Philip J Rybczynski